Category - Developments

Developments

Zenabis Global and Heritage Cannabis to enter mutual supply and services agreements

Zenabis Global (TSXV:ZENA) and Heritage Cannabis (CSE:CANN; OTC:HERTF) signed a supply and services agreement for Zenabis to supply dried cannabis flower to Heritage for the extraction of CBD and THC. The term sheet...

May 9, 2019

Developments

Biohaven Pharma reports new Phase 2/3 data for rimegepant for migraines

Biohaven Pharmaceutical Holding (NYSE:BHVN) reported new data from its Phase 2/3 trial of rimegepant, and orally-dosed calcitonin gene-related peptide (CGRP) antagonist, for the prevention of migraines. During the third...

May 9, 2019

Developments

Alder BioPharma reports new Phase 3 data for eptinezumab for migraines

Alder BioPharma (NASDAQ:ALDR) reported new data from its Phase 3 trial of eptinezumab, a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP), for the prevention of migraines. Nearly 60% of patients...

May 9, 2019

Developments

Tilray to boost Canadian cannabis production and manufacturing

Tilray (NASDAQ:TLRY) plans to spend $32.6-million to increase its Canadian cannabis production and manufacturing capacity by 203,000 square feet at three plants. The three Canadian sites are at Leamington and London...

May 8, 2019

Developments

IntelGenx and Aquestive Therapeutics in global collaboration for Tadalafil

IntelGenx (TSXV:IGX; OTCQX:IGXT) entered into a definitive worldwide agreement with Aquestive Therapeutics (NASDAQ:AQST), a specialty pharmaceutical company, for the co-development and commercialization of Tadalafil...

May 8, 2019

Developments

Theralase receives notice of acceptance from Chinese Patent Office

The Chinese Patent Office issued a notice of acceptance to Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) for a patent application about its multi-wavelength photodynamic therapy (PDT). The patent validates the...

May 7, 2019

Developments

Canopy Growth unveils new cannabis commercial medical and research unit, Spectrum Therapeutics

Canopy Growth (TSX:WEED; NYSE:CGC) unveiled Spectrum Therapeutics, a new global brand that will encompass all of the company’s ongoing commercial medical and clinical research operations. These include Spectrum...

May 7, 2019

Developments

Profound Medical submits 510(k) application for TULSA-PRO; Reports 292% increase in Q1 revenues

The FDA has accepted Profound Medical’s (TSX:PRN; OTCQX:PRFMF) 510(k) application for premarket clearance of TULSA-PRO, a novel technology that combines real-time MRI, robotically-driven transurethral ultrasound and...

May 6, 2019

Developments

Zynerba Pharma Zygel gets FDA fast track designation for Fragile X

The FDA granted Zynerba Pharma’s (NASDAQ:ZYNE) Zygel fast track designation for behavioral symptoms associated with Fragile X syndrome. Fragile X syndrome, a rare genetic condition caused by a mutation in the X...

May 6, 2019

Developments

Savara gets FDA fast track designation for autoimmune lung disease

The FDA granted Savara’s (NASDAQ:SVRA) Molgradex fast track designation for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). aPAP occurs when the body’s immune system attacks granulocyte-macrophage...

May 6, 2019

Category - Developments

Subscribe